Patents by Inventor Ching-Shih Chen

Ching-Shih Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8741944
    Abstract: A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of Formula I: wherein X wherein X is —CF3, Ar is selected from and R is selected from where R? is L-Lys, D-Lys, ?-Ala, L-Lue, L-Ile, Phe, SO2CH2CH2NH2, SO2NH2, Asn, Glu or Gyl, and R? is methyl, ethyl, allyl, CH2CH2OH, CH2CN, CH2CH2CN, CH2CONH2,
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: June 3, 2014
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Hao-Chieh Chiu, Dasheng Wang
  • Patent number: 8680133
    Abstract: Compounds and methods for treating cancer or inducing apoptosis in proliferating cells. The compounds are shown in formula I: wherein X is selected from hydroxyl, thiol, and amino; Y is selected from carboxyl and sulfonyl; R1, R2, R3, and R4 are selected from hydrogen, lower alkyl, and combinations thereof; R5, R6, and R7 are selected from hydrogen, halo, ni tro, amino, methoxy, and combinations thereof; and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: March 25, 2014
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Jing-Ru Weng
  • Patent number: 8658647
    Abstract: A number of compounds and use of the compounds in a method for treating or preventing cancer in a subject by administering to the subject a pharmaceutical composition including a compound of formula I or a pharmaceutically acceptable salt thereof are described. The compounds can also be used to inhibit integrin-linked kinase in a cell, which has an effect on the Akt signaling pathway.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: February 25, 2014
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Su-Lin Lee, Samuel K. Kulp
  • Publication number: 20140031388
    Abstract: Anticancer compounds according to formula I are described herein. wherein R1, R2, R3 and R4 are selected from H, CH3, OH, SH, OCH3, NHR?, halogen, CF3, N-linked pyrrolidine, and SO2NHR?, or any combination thereof; R5 is an alkyl, alkenyl, or alkaryl group including from 4 to 11 carbons, X is selected from CH2, CHOH, C?O, S?O, O?S?O, and an oxetane ring, Y is selected from CH2, O, and NH, and R? is a H, aryl, or a lower alkyl group, or pharmaceutically acceptable salts thereof. The compounds have been shown to facilitate site-specific dephosphorylation of Akt at Ser-473, thereby inactivating Akt and decreasing dysregulation of Akt signaling that can occur in cancer cells.
    Type: Application
    Filed: July 26, 2013
    Publication date: January 30, 2014
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
  • Patent number: 8633161
    Abstract: The invention provides for methods of treating a mammal who has a BCR/ABL-mediated leukemia, including chronic myelogenous leukemia (CML), particularly the blast crisis stage of CML, Philadelphia-positive acute lymphoblastic leukemia (Ph?-ALL), and refractory leukemias. The invention also provides for compounds for the treatment of these leukemias and methods of identifying anti-leukemic agents.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: January 21, 2014
    Assignee: The Ohio State University Research Foundation
    Inventors: Danilo Perrotti, Paolo Neviani, Ramasamy Santhanam, John C. Byrd, Guido Marcucci, Natarajan Muthusamy, Ching-Shih Chen
  • Patent number: 8580827
    Abstract: A series of celecoxib derivatives defined by Formula I: were prepared and evaluated for their ability to inhibit the gram-negative bacteria Francisella tularensis. Pharmaceutical compositions including celecoxib derivatives and their use in methods for treating or preventing infection by Francisella tularensis in a subject are described.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: November 12, 2013
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Hao-Chieh Chiu, Samuel Kulp, John S. Gunn, Larry S. Schlesinger
  • Publication number: 20130289004
    Abstract: A method of treating infection by Staphylococcus in a subject by administering a pharmaceutical composition including a celecoxib derivative of formula I or a pharmaceutically acceptable salt thereof is described. The preparation of numerous celecoxib derivatives for testing as potential anti-staphylococcal agents is also described.
    Type: Application
    Filed: October 31, 2011
    Publication date: October 31, 2013
    Applicant: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Hao-Chieh Chiu, Dasheng Wang, Samuel K. Kulp
  • Patent number: 8546441
    Abstract: A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula I: wherein X is selected from the group consisting of alkyl and haloalkyl; Ar is an aryl radical selected from the group consisting of phenyl, biphenyl, naphthyl, anthryl, phenanthryl, and fluorenyl; and wherein Ar is optionally substituted with one or more radicals selected from the group consisting of halo, C1-C4 alkyl, C1-C4 haloalkyl, azido, C1-C4 azidoalkyl, aryl, alkylaryl, haloaryl, haloalkylaryl, and combinations thereof; and R is selected from the group consisting of nitrile, acetonitrile, ethylnitrile, propylnitrile, carboxamide, amidine, tetrazole, oxime, hydrazone, acetamidine, aminoacetamide, guanidine, and urea. Also provided are methods of using the compounds for the treatment and prevention of cancer in humans.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: October 1, 2013
    Assignee: The Ohio State University Research Foundation
    Inventor: Ching-Shih Chen
  • Patent number: 8546397
    Abstract: A number of DNA methylation inhibitors are described. The DNA methylation inhibitors were identified using a two-component enhanced green fluorescent protein reporter system to screen a compound library containing procainamide derivatives. The DNA methylation inhibitors can be used for cancer therapy and prevention.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: October 1, 2013
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Arthur Y. Shaw, Yu-Wei Leu, Shu-Huei Hsiao
  • Patent number: 8541460
    Abstract: Use of a new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula I for inducing apoptosis in unwanted rapidly proliferating cells, for treating, inhibiting, or delaying the onset of cancer, and for preventing restenosis in a subject that has undergone an angioplasty or stent: wherein X is selected from the group consisting of alkyl and haloalkyl; Ar is an aryl radical selected from the group consisting of phenyl, biphenyl, naphthyl, anthryl, phenanthryl, and fluorenyl; and wherein Ar is optionally substituted with one or more radicals selected from the group consisting of halo, C1-C4 alkyl, C1-C4 haloalkyl, azido, C1-C4 azidoalkyl, aryl, akylaryl, haloaryl, haloalkylaryl, and combinations thereof; and R is selected from the group consisting of nitrile, acetonitrile, ethylnitrile, propylnitrile, carboxamide, amidine, tetrazole, oxime, hydrazone, acetamidine, aminoacetamide, guanidine, and urea.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: September 24, 2013
    Assignee: The Ohio State University
    Inventor: Ching-Shih Chen
  • Publication number: 20130237575
    Abstract: A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of Formula I: wherein X wherein X is —CF3, Ar is selected from and R is selected from where R? is L-Lys, D-Lys, ?-Ala, L-Lue, L-Ile, Phe, SO2CH2CH2NH2, SO2NH2, Asn, Glu or Gyl, and R? is methyl, ethyl, allyl, CH2CH2OH, CH2CN, CH2CH2CN, CH2CONH2,
    Type: Application
    Filed: April 24, 2013
    Publication date: September 12, 2013
    Applicant: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Hao-Chieh Chiu, Dasheng Wang
  • Patent number: 8478368
    Abstract: A portable electronic device includes a main body, a cap body and a hinge assembly. The cap body is movably attached to the main body, and the hinge assembly is disposed between the main body and the cap body. The hinge assembly includes a sliding portion and a rotating portion connected to each other. When the cap body and the main body are totally overlapped, the cap body is selectively to rotate or to slide with respect to the main body over the hinge assembly.
    Type: Grant
    Filed: May 14, 2008
    Date of Patent: July 2, 2013
    Assignee: HTC Corporation
    Inventors: Chang-Hwang Chiou, Ching-Shih Chen, Yun-Long Tun
  • Patent number: 8461362
    Abstract: Tocopheryl succinate derivatives according to formula I: are described. These compounds increase the activity of protein phosphatase 2A, can be included in pharmaceutical compositions, and can be used for the treatment of androgen receptor-dependent cancers such as prostate cancer.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: June 11, 2013
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
  • Patent number: 8445483
    Abstract: A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of Formula I: wherein X wherein X is —CF3, Ar is selected from and R is selected from where R? is L-Lys, D-Lys, ?-Ala, L-Lue, L-Ile, Phe, SO2CH2CH2NH2, SO2NH2, Asn, Glu or Gyl, and R? is methyl, ethyl, allyl, CH2CH2OH, CH2CN, CH2CH2CN, CH2CONH2,
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: May 21, 2013
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Hao-Chieh Chiu, Dasheng Wang, John S. Gunn, Larry S. Schlesinger
  • Publication number: 20130109681
    Abstract: A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of Formula I: wherein X wherein X is —CF3, Ar is selected from and R is selected from where R? is L-Lys, D-Lys, ?-Ala, L-Lue, L-Ile, Phe, SO2CH2CH2NH2, SO2NH2, Asn, Glu or Gyl, and R? is methyl, ethyl, allyl, CH2CH2OH, CH2CN, CH2CH2CN, CH2CONH2,
    Type: Application
    Filed: October 7, 2011
    Publication date: May 2, 2013
    Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Ching-Shih Chen, Hao-Chieh Chiu, Dasheng Wang, John S. Gunn, Larry S. Schlesinger
  • Patent number: 8383656
    Abstract: A method of inhibiting glycolysis in a subject by administering a pharmaceutical composition including a thiazolidinedione derivative to the subject is described. The thiazolidinedione derivatives are effective energy restriction mimetic agents, and can therefore be used to treat or prevent cancer in a subject, treat metabolic disorder, or increase the longevity of a subject. Various thiazolidinedione derivatives are also suitable for activating adenosine phosphate-activated protein kinase or inhibiting IL-6 expression.
    Type: Grant
    Filed: October 11, 2010
    Date of Patent: February 26, 2013
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Jih-Hwa Guh
  • Patent number: 8377948
    Abstract: Antitumor compounds based on the ?1-adrenoceptor antagonist, doxazosin, as well as compositions and methods of use. The disclosed compounds induce apoptosis in cancer cells.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: February 19, 2013
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Yeng-Jeng Shaw, Jason B. Garrison, Natasha Kyprianou
  • Patent number: 8362071
    Abstract: Vitamin E succinate derivatives according to formula I: are described. These compounds can be included in pharmaceutical compositions, and can be used for the treatment of cancers such as metastatic cancer and as antiadhesive agents.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: January 29, 2013
    Assignee: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
  • Publication number: 20130005788
    Abstract: A series of celecoxib derivatives defined by Formula I: were prepared and evaluated for their ability to inhibit the gram-negative bacteria Francisella tularensis. Pharmaceutical compositions including celecoxib derivatives and their use in methods for treating or preventing infection by Francisella tularensis in a subject are described.
    Type: Application
    Filed: September 12, 2012
    Publication date: January 3, 2013
    Applicant: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Ching-Shih Chen, Hao-Chieh Chiu, Samuel Kulp, John S. Gunn, Larry S. Schlesinger
  • Patent number: 8318812
    Abstract: Methods—for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or a derivative, pharmaceutically acceptable salt thereof, or a prodrug thereof to a subject.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: November 27, 2012
    Assignee: The Ohio State University Research Foundation
    Inventors: John C. Byrd, Danilo Perrotti, Ching-Shih Chen, James T. Dalton, Frank Frissora, Xiaobin Zhao, Qing Liu, Natarajan Muthusamy